Corporate Profile

Theseus Pharmaceuticals is passionately committed to improving the lives of cancer patients by working to outsmart cancer resistance. Led by a team of targeted oncology pioneers with a proven track record developing and commercializing cancer therapeutics, the Company is developing next-generation tyrosine kinase inhibitors (TKIs): “pan-variant” targeted therapies that address all major drug resistant mutations. Theseus believes a pan-variant approach is the most effective way to address cancer resistance.

The Company’s lead program, THE-630, is a pan-variant KIT inhibitor for patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing THE-349: a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC). Finally, Theseus is also developing a series of next-generation, pan-variant TKI molecules targeting BCR-ABL mutations for the treatment of refractory chronic myeloid leukemia (CML) and front-line Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). 

Corporate Presentation
Stock Price
Recent News Releases from Theseus
Mar 9, 2023

THE-630 phase 1 preliminary dose-escalation data anticipated in Q2 2023; additional data including dose levels projected preclinically to provide pan-variant KIT coverage planned for Q4 2023 IND...

Feb 7, 2023

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and...

Jan 5, 2023

Progressing Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose-escalation data anticipated in Q2 2023 with additional data expected in Q4 2023 IND submission for 4G EGFR...

View All

Recent Events
Thursday, February 16, 2023
10:40am EST

View all